CymaBay Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need. Wholly owned lead asset, Seladelpar, is a potent, selective, orally active PPARδ agonist currently in development for the treatment of patients with the autoimmune liver disease, primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Two Phase 2 studies of seladelpar established proof of concept in PBC. Additionally, CymaBay has out-licensed US rights to Arhalofenate to Kowa Pharmaceuticals America, Inc. Arhalofenate is a potential urate-lowering anti-flare therapy that has been found to reduce painful flares in joints while at the same time lowering serum uric acid by promoting excretion of uric acid by the kidney. This dual action addresses both the signs and symptoms of gout while managing the underlying pathophysiology of hyperuricemia. CymaBay retains full development and commercialization rights for arhalofenate outside the U.S.
Employees: 51-200
Total raised: $100M
Founded date: 1988
Investors 6
| Date | Name | Website |
| - | Foresite C... | foresiteca... |
| - | Omega Fund... | omegafunds... |
| 23.03.2023 | Avoro Capi... | avorocapit... |
| 03.08.2021 | Abingworth... | abingworth... |
| - | VantagePoi... | vpcp.com |
| - | Bay City C... | baycitycap... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 02.08.2021 | - | $100M | Abingworth... |
Mentions in press and media 11
| Date | Title | Description |
| 08.08.2024 | Gilead quarterly profit beats Street estimates, revenue up 5% | Healthcare & PharmaceuticalsCommercial Strategy Gilead quarterly profit beats Street estimates, revenue up 5% By Deena BeasleyAugust 8, 20248:05 PM UTCUpdated ago Text Small Text Medium Text Large Text Share X Facebook Linkedin Email Li... |
| 25.03.2024 | Gilead Sciences Completes Acquisition of CymaBay, for Approximately $4.3 Billion | Gilead Sciences (Nasdaq: GILD), a Foster City, CA-based biopharmaceutical company, acquired CymaBay Therapeutics, Inc. (Nasdaq: CBAY), CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a Newark-based biopharmaceutical company focused on innovative... |
| 08.03.2024 | Seladelpar (MBX-8025) Market Overview and Outlook 2024-2032: Product Overview, Regulatory Milestones, Global Activities, Patents, Market Assessment, Emerging Therapies, SWOT Analysis | - |
| 06.02.2023 | CymaBay Therapeutics to Present at the SVB Securities Global Biopharma Conference | /EIN News/ -- NEWARK, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need,... |
| 03.11.2022 | CymaBay Therapeutics to Present at Upcoming Investment Conferences | /EIN News/ -- NEWARK, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need,... |
| 11.11.2021 | CymaBay Reports Third Quarter and Nine Months Ended September 30, 2021 Financial Results and Provides Corporate Update | Over 100 clinical sites now activated in RESPONSE Phase 3 registration study of seladelpar for patients with primary biliary cholangitis (PBC) Additional data from prior studies of seladelpar in patients with PBC to be featured at The Liver... |
| 12.08.2021 | CymaBay Therapeutics : Reports Second Quarter and Six Months Ended June 30, 2021 Financial Results and Provides Corporate Update | Secured up to $100 million of additional development funding through a non-dilutive financing transaction with Abingworth Funds the Phase 3 development program for seladelpar in primary biliary cholangitis (PBC), including the Phase 3 RESPO... |
| 02.08.2021 | CymaBay secures $100M to bankroll phase 3 development of resurrected liver drug Clinical Quality Oversight Forum | A little over a year after resurrecting the liver disease drug seladelpar, CymaBay Therapeutics now has $100 million to bankroll a phase 3 study of the drug. RELATED: CymaBay resurrects seladelpar 8 months after NASH flop In November, the N... |
| 02.08.2021 | CymaBay Announces $100 Million Non-Dilutive Financing with Abingworth | - |
| 02.08.2021 | CymaBay Therapeutics : Announces $100 Million Non-Dilutive Financing with Abingworth | Risk-sharing agreement with Abingworth will fund seladelpar Phase 3 development program for PBC CymaBay retains full worldwide commercial rights to seladelpar NEWARK, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NAS... |
Show more